Clinical trial
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
NCT00079768 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00079768 |
|---|---|
| Title | Alemtuzumab to Treat Sporadic Inclusion Body Myositis |
| Official title | Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myositis, Inclusion Body |
| Intervention type | Drug |
| Interventions | Alemtuzumab (Campath) |
| Enrollment | 20 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Mar 12, 2004 |
| Last update posted | Jun 17, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: